|
|
Diabetic Macular Edema: Employing Inflammatory Markers to Predict Improved Visual Outcomes
Real-world outcomes with intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the treatment of patients with diabetic macular edema (DME) do not always replicate those seen in clinical studies. In part, these discrepancies are due to treatment burden, lack of adherence, undertreatment, and incomplete response to anti-VEGF therapies. The identification of several inflammatory cytokines in the aqueous and vitreous humor whose concentrations correlate closely with the severity o... |
|
|
Diabetic Macular Edema: Employing Inflammatory Markers to Predict Improved Visual Outcomes
Real-world outcomes with intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the treatment of patients with diabetic macular edema (DME) do not always replicate those seen in clinical studies. In part, these discrepancies are due to treatment burden, lack of adherence, undertreatment, and incomplete response to anti-VEGF therapies. The identification of several inflammatory cytokines in the aqueous and vitreous humor whose concentrations correlate closely with the severity o... |
|
|
Geographic Atrophy: Rapid Response from ARVO
Geographic atrophy (GA) is a pathological deterioration of the retina seen in the late stages of age-related macular degeneration (AMD). It affects 20% of people with AMD, and its prevalence increases exponentially with age. Until recently, there were no treatment options for GA, but investigation into the complement system and its role in the pathogenesis of GA has led to targeted therapies that have revolutionized the treatment paradigm. Because of the recent approval of one of these therapi... |
|
|
Ace the Case: A 65-Year-Old Woman With Chronic Diabetic Macular Edema in Both Eyes
In this clinical case review, Dr. Sara Haug explores considerations for the management of a patient with DME who is receiving monthly anti-VEGF therapy without attaining disease control. |
|
|
The Art of Ophthalmology Medicine: Individualizing Therapy in Neovascular Age-Related Macular Degeneration in an Era of Expanded Treatment Options; AMD Virtual Pathways Activity
Target Audience
This initiative is designed to meet the educational needs of retina/ophthalmology, optometry, managed care, primary care/internal medicine, diabetes education, and cardiology/endocrinology sub-specialties.
Program Overview
This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD) based on patient-, disease-, and treatment-related factors. Listen to a retina expert talk about some of the technological ... |
|
|
The Art of Ophthalmology Medicine: Individualizing Therapy in Neovascular Age Related Macular Degeneration in an Era of Expanded Treatment Options; nAMD Day in the Life
Target Audience
This initiative is designed to meet the educational needs of retina/ophthalmology, optometry, managed care, primary care/internal medicine, diabetes education, and cardiology/endocrinology sub-specialties.
Program Overview
This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD). Providers will learn about the safety, efficacy, and durability of established and emerging nAMD therapies, as well as tec... |
|